India's Sun Pharma Advanced slumps after drug trial for early Parkinson's patients fails

Sun Pharma Advanced Research

10/04/2024 05:02

** Shares of Sun Pharma Advanced Research  SPRC.NS  down
exchange-allowed maximum of 5% to 429.7 rupees 
    ** The bio-pharma firm's study on using Vodobatinib drug on
early Parkinson's patients did not show any benefits 
    ** Stock has been trading above its 200-day simple moving
avg since June 2023
    ** Including session's drop, shares up ~50% YTD 



 (Reporting by Manvi Pant in Bengaluru)
 ((Manvi.Pant@thomsonreuters.com; +918447554364;))